clinical trial · NCT07039890
To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
Humanis Saglık Anonim Sirketi·phase1·completed·n = 40
Type 2 Diabetes Mellitus (T2DM)Empagliflozin + Linagliptin filmcoated tabletsGlyxambi film-coated tablets
brief summary
To compare and evaluate the oral bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg film-coated tablets with that of Glyxambi 10 mg/ 5 mg film-coated tablets in healthy, adult, human subjects under fasting conditions.
started
Mar 8, 2025
primary completion
May 14, 2025
completion
Jun 5, 2025
last updated
Jun 26, 2025
official title
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Condition.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol